Applied dna announces new follow-on lineadna order from global ivd manufacturer for use in cancer diagnostic application

Stony brook, ny / access newswire / july 24, 2025 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in synthetic dna manufacturing powered by scalable pcr platforms, today announced it received a seventh follow-on order valued at more than $600,000 for a multi-gram quantity of lineadna™. the follow-on order was placed by a global manufacturer of in vitro diagnostics (ivds) under a long-standing supply agreement for the bulk manufacture of lineadna used as a functional component of a cancer diagnostic test.
APDN Ratings Summary
APDN Quant Ranking